Panos Kanavos
Biographic Data
| ID | 1724263 |
|---|---|
| NAME | Panos Kanavos |
| GIVEN NAMES | Panos |
| FAMILY NAME | Kanavos |
| SIGNATURE | KANAVOS P |
| AFFILIATIONS | London School of Economics and Political Science |
| ORCID | 0000-0001-9518-3089 |
| VERIFIED | Yes |
| TOTAL WORKS | 16 |
| TOTAL CITATIONS | 13 |
| AUTHOR COUNT | 16 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2009 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 2 |
Algorithms and heuristics of health technology assessments
A structured methodology for essential medicines lists and health emergency stockpiles
The methodological application generated a ranking of therapeutic areas based on expected "population health loss" index, while addressing evidence uncertainty. The methodology can be adapted for other EMLs and emergency stockpile contexts to inform medicines selection
Road traffic mortality and economic uncertainty
Previous studies have shown that financial turbulence is associated with a short-term increase in road traffic collisions, largely due to drivers' emotional state, distraction, sleep deprivation and alcohol consumption. In this paper we advance this debate by studying the association between economic uncertainty and road traffic mortality in the United States. We used a State-level uncertainty index and State fatalities for the period 2008-2017 a…
How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada
There is a growing disconnect between regulatory agencies that are promoting expedited approval to medicines based on early phase clinical evidence and health technology assessment (HTA) agencies that require robust clinical evidence to inform coverage decisions. This paper provides an assessment of the evidence gap between regulatory and HTA agencies on medicines receiving conditional marketing authorisation (CMA) and examines how HTA agencies i…
Sin taxes and their effect on consumption, revenue generation and health improvement
Sin or public health taxes are excise taxes imposed on the consumption of potentially harmful goods for health [sugar-sweetened beverages (SSBs), tobacco, alcohol, among others], aiming to reduce consumption, raise additional revenue and/or improve population health. This paper assesses the extent to which sin taxes (a) can reduce consumption of potentially harmful goods, (b) raise revenue for national health systems and (c) contribute to populat…
Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe
Payers have increasingly implemented a variety cost-containment measures to promote sustainability in the pharmaceutical sector. This paper provides an assessment of a range of different applications of pharmaceutical budgets and assesses their impact in the context of health financing goals. A comprehensive literature review was carried out in order to identify evidence on the presence and impact of pharmaceutical budget-setting and capping mech…
Multiple Criteria Decision Analysis for HTA across four EU Member States
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period
We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of government forecasts of drug demand. We calculated Herfindahl-Hirschman indexes to measure market concentration levels based on all pharmaceutical tender contracts issued by the South African government between 2003 and 2016 (n = 8701). We estimated price indexes to tr…
Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result …
Dealing with uncertainty and high prices of new medicines
Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
BACKGROUND: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting the economically active population. The objective of this paper is to identify and discuss costs, outcomes and some of the challenges of diabetes care in Italy in the context of recent policy changes. METHODS: The s…
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil
BACKGROUND: With an estimated 74% of all deaths attributable to non-communicable diseases (NCDs) in 2010, NCDs have become a major health priority in Brazil. The objective of the study was to conduct a comprehensive literature review on diabetes in Brazil; specifically: the epidemiology of type 2 diabetes, the availability of national and regional sources of data (particularly in terms of direct and indirect costs) and health policies for the man…
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines
BACKGROUND: To evaluate medicine prices, availability and affordability in Brazil, considering the differences across three types of medicines (originator brands, generics and similar medicines) and different types of facilities (private pharmacies, public sector pharmacies and "popular pharmacies"). METHODS: Data on prices and availability of 50 medicines were collected in 56 pharmacies across six cities in Southern Brazil using the World Health…
The less healthy urban population
The findings suggest that policy targeting the poor, especially the urban poor, is needed in order to reduce health inequality
Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público
The overall availability of the drugs surveyed was higher than the 80% recommended by WHO. However, some treatments were not available, or had limited availability in the public system. Concerning affordability, the number of salary days required to buy these drugs may affect the continuation of drug treatments for chronic diseases
Benefits of global partnerships to facilitate access to medicines in developing countries
BACKGROUND: Access to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively, but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries…
Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result …
Dealing with uncertainty and high prices of new medicines
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period
We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of government forecasts of drug demand. We calculated Herfindahl-Hirschman indexes to measure market concentration levels based on all pharmaceutical tender contracts issued by the South African government between 2003 and 2016 (n = 8701). We estimated price indexes to tr…
Benefits of global partnerships to facilitate access to medicines in developing countries
BACKGROUND: Access to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia (CML), a rare disease, can be treated effectively, but the pharmaceutical treatment available (imatinib) is costly and unaffordable by most patients. GIPAP, is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries…
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines
BACKGROUND: To evaluate medicine prices, availability and affordability in Brazil, considering the differences across three types of medicines (originator brands, generics and similar medicines) and different types of facilities (private pharmacies, public sector pharmacies and "popular pharmacies"). METHODS: Data on prices and availability of 50 medicines were collected in 56 pharmacies across six cities in Southern Brazil using the World Health…
The less healthy urban population
The findings suggest that policy targeting the poor, especially the urban poor, is needed in order to reduce health inequality
Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público
The overall availability of the drugs surveyed was higher than the 80% recommended by WHO. However, some treatments were not available, or had limited availability in the public system. Concerning affordability, the number of salary days required to buy these drugs may affect the continuation of drug treatments for chronic diseases
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil
BACKGROUND: With an estimated 74% of all deaths attributable to non-communicable diseases (NCDs) in 2010, NCDs have become a major health priority in Brazil. The objective of the study was to conduct a comprehensive literature review on diabetes in Brazil; specifically: the epidemiology of type 2 diabetes, the availability of national and regional sources of data (particularly in terms of direct and indirect costs) and health policies for the man…
Cost, outcomes, treatment pathways and challenges for diabetes care in Italy
BACKGROUND: In Italy both incidence and prevalence of diabetes are increasing and age at diagnosis is decreasing in type 2 diabetes. Diabetes is one of the major causes of morbidity in Italy, causing several disabilities and affecting the economically active population. The objective of this paper is to identify and discuss costs, outcomes and some of the challenges of diabetes care in Italy in the context of recent policy changes. METHODS: The s…
Dealing with uncertainty and high prices of new medicines
Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result …
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period
We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of government forecasts of drug demand. We calculated Herfindahl-Hirschman indexes to measure market concentration levels based on all pharmaceutical tender contracts issued by the South African government between 2003 and 2016 (n = 8701). We estimated price indexes to tr…
Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe
Payers have increasingly implemented a variety cost-containment measures to promote sustainability in the pharmaceutical sector. This paper provides an assessment of a range of different applications of pharmaceutical budgets and assesses their impact in the context of health financing goals. A comprehensive literature review was carried out in order to identify evidence on the presence and impact of pharmaceutical budget-setting and capping mech…
Multiple Criteria Decision Analysis for HTA across four EU Member States
Sin taxes and their effect on consumption, revenue generation and health improvement
Sin or public health taxes are excise taxes imposed on the consumption of potentially harmful goods for health [sugar-sweetened beverages (SSBs), tobacco, alcohol, among others], aiming to reduce consumption, raise additional revenue and/or improve population health. This paper assesses the extent to which sin taxes (a) can reduce consumption of potentially harmful goods, (b) raise revenue for national health systems and (c) contribute to populat…
How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada
There is a growing disconnect between regulatory agencies that are promoting expedited approval to medicines based on early phase clinical evidence and health technology assessment (HTA) agencies that require robust clinical evidence to inform coverage decisions. This paper provides an assessment of the evidence gap between regulatory and HTA agencies on medicines receiving conditional marketing authorisation (CMA) and examines how HTA agencies i…
Algorithms and heuristics of health technology assessments
A structured methodology for essential medicines lists and health emergency stockpiles
The methodological application generated a ranking of therapeutic areas based on expected "population health loss" index, while addressing evidence uncertainty. The methodology can be adapted for other EMLs and emergency stockpile contexts to inform medicines selection
Road traffic mortality and economic uncertainty
Previous studies have shown that financial turbulence is associated with a short-term increase in road traffic collisions, largely due to drivers' emotional state, distraction, sleep deprivation and alcohol consumption. In this paper we advance this debate by studying the association between economic uncertainty and road traffic mortality in the United States. We used a State-level uncertainty index and State fatalities for the period 2008-2017 a…
Medicine (13 works) · Economics (10 works) · Health Systems, Economic Evaluations, Quality of Life (10 works) · Pharmaceutical Economics and Policy (9 works) · Environmental health (7 works) · Economic growth (6 works) · Political science (6 works) · Public health (6 works) · Business (5 works) · Health care (5 works)